Education
About Us
Working with TipRanks
Follow Us
Palvella Therapeutics (PVLA)
NASDAQ:PVLA
Total Valuation
Palvella Therapeutics has a market cap or net worth of $1.19B. The enterprise value is $646.07M.
Market Cap$1.19B
Enterprise Value$646.07M
Share Statistics
Palvella Therapeutics has 11,836,490 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,836,490
Owned by Insiders2.16%
Owned by Institutions45.35%
Financial Efficiency
Palvella Therapeutics’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -18.50%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-18.50%
Return on Capital Employed (ROCE)-0.18
Revenue Per Employee0.00
Profits Per Employee-1.25M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Palvella Therapeutics is ―. Palvella Therapeutics’s PEG ratio is 0.01.
PE Ratio―
PS Ratio0.00
PB Ratio0.43
Price to Fair Value0.43
Price to FCF-2.46
Price to Operating Cash Flow-107.38
PEG Ratio0.01
Income Statement
In the last 12 months, Palvella Therapeutics had revenue of 0.00 and earned -17.43M in profits. Earnings per share was -7.83.
Revenue0.00
Gross Profit0.00
Operating Income-14.10M
Pretax Income-17.43M
Net Income-17.43M
EBITDA-13.12M
Earnings Per Share (EPS)-7.83
Cash Flow
In the last 12 months, operating cash flow was -17.59M and capital expenditures 0.00, giving a free cash flow of -17.59M billion.
Operating Cash Flow-17.59M
Free Cash Flow-17.59M
Free Cash Flow per Share-1.49
Dividends & Yields
Palvella Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.06
52-Week Price Change744.02%
50-Day Moving Average86.47
200-Day Moving Average48.36
Relative Strength Index (RSI)55.41
Average Volume (3m)297.26K
Important Dates
Palvella Therapeutics upcoming earnings date is Apr 6, 2026, TBA (Confirmed).
Last Earnings DateNov 11, 2025
Next Earnings DateApr 6, 2026
Ex-Dividend Date―
Financial Position
Palvella Therapeutics as a current ratio of 7.33, with Debt / Equity ratio of 0.00%
Current Ratio7.33
Quick Ratio7.33
Debt to Market Cap0.00
Net Debt to EBITDA6.37
Interest Coverage Ratio-3.26
Taxes
In the past 12 months, Palvella Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Palvella Therapeutics EV to EBITDA ratio is 4.34, with an EV/FCF ratio of 5.25.
EV to Sales0.00
EV to EBITDA4.34
EV to Free Cash Flow5.25
EV to Operating Cash Flow5.25
Balance Sheet
Palvella Therapeutics has $63.57M in cash and marketable securities with $0.00 in debt, giving a net cash position of $63.57M billion.
Cash & Marketable Securities$63.57M
Total Debt$0.00
Net Cash$63.57M
Net Cash Per Share$5.37
Tangible Book Value Per Share$28.13
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Palvella Therapeutics is $180.57, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$180.57
Price Target Upside80.08% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast―
EPS Growth Forecast―